Clinton Bybee's Net Worth

$2.01 Billion

Estimate Recalculated Mar 1, 2024 04:18PM EST

Who is Clinton Bybee?

Clinton Bybee has an estimated net worth of $2.01 Billion. This is based on reported shares across multiple companies, which include Sana Biotechnology, Inc., KYTHERA BIOPHARMACEUTICALS INC, PHASERX, INC., Neumora Therapeutics, Inc., Lyell Immunopharma, Inc., ADESTO TECHNOLOGIES Corp, AGIOS PHARMACEUTICALS INC, NeurogesX Inc, VBI VACCINES INC., Receptos, Inc., Gossamer Bio, Inc., Scholar Rock Holding Corp, Pulmatrix, Inc., Karuna Therapeutics, Inc., bluebird bio, Inc., Denali Therapeutics Inc., FATE THERAPEUTICS INC, Sage Therapeutics, Inc., Vir Biotechnology, Inc., Beam Therapeutics Inc., Metacrine, Inc., Bellerophon Therapeutics, Inc., Unity Biotechnology, Inc., Syros Pharmaceuticals, Inc., Codiak BioSciences, Inc., Sienna Biopharmaceuticals, Inc., Juno Therapeutics, Inc., Homology Medicines, Inc., Achaogen Inc, Trubion Pharmaceuticals, Inc, CELEBRATE EXPRESS, INC., 908 Devices Inc., Quanterix Corp, Twist Bioscience Corp, XTERA COMMUNICATIONS, INC., ALNYLAM PHARMACEUTICALS INC, IMPINJ INC, XCYTE THERAPIES INC, and ILLUMINA INC.

SEC CIK

Clinton Bybee's CIK is 0001219043

Past Insider Trading and Trends

2021 was Clinton Bybee's most active year for acquiring shares with 43 total transactions. Clinton Bybee's most active month to acquire stocks was the month of July. 2021 was Clinton Bybee's most active year for disposing of shares, totalling 48 transactions. Clinton Bybee's most active month to dispose stocks was the month of September. 2023 saw Clinton Bybee paying a total of $25,500,000.00 for 18,924,704 shares, this is the most they've acquired in one year. In 2012 Clinton Bybee cashed out on 2,308,783 shares for a total of $919,768.08, their largest year based on trade value.

Attention insiders: Dive deeper into market movements and stay ahead of the curve with Benzinga Pro! From up-to-the-second news to audio squawks and interactive data tools, it's everything you need to supercharge your trading strategy. Experience the Benzinga Pro advantage today and transform the way you trade with our exclusive free trial!

NeurogesX Inc No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+71.38%
1.74M
$1.65
$2,877,906.90
4.19M
Jul 21
Form 4
+18.54%
382.17K
$6.18
$2,361,810.60
2.44M
Dec 24
Form 4
+1,015.12%
2.3M
2.53M
May 7
Form 4
227K
$11.00
$2,497,000.00
227K
May 2
Form 3
0
0
No matching records found

XTERA COMMUNICATIONS, INC. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
0
0
Oct 11
Form 4
0
0
Sep 27
Form 4
0
0
Sep 13
Form 4
+97.86%
1.86M
$5.00
$1,500,000.00
3.77M
Nov 17
Form 4
+97.86%
1.86M
$5.00
$1,500,000.00
3.77M
Nov 17
Form 3
0
0
Form 3
0
0
No matching records found

Trubion Pharmaceuticals, Inc No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-2.36M
0
Oct 28
Form 4
+3,337.93%
2.29M
2.36M
Oct 23
Form 4
+187.86%
44.64K
$13.00
$580,320.00
68.4K
Oct 17
Form 3
0
0
No matching records found

CELEBRATE EXPRESS, INC. No price found

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
-100.00%
-1.04M
0
Aug 29
Form 4
1.03M
1.03M
Oct 25
Form 3
0
0
No matching records found

Sana Biotechnology, Inc. (SANA) Snapshot price: $6.175

Investor

Form Type
Δ Own
Qty.
Price
Size ($)
Own
Filing Date
Type
Is Scheduled
Trade Dates
Form 4
+5.39%
1.82M
$5.50
$9,999,995.50
35.56M
Feb 8
Form 4
+14,957.26%
43.75M
44.04M
Feb 8
Form 3
0
0
No matching records found